About OrchestratePharma
Patient oriented — Faster time to market — Lowered risk — Exceptional ROI
Patient Oriented
Every decision starts with the patient. We focus on unmet medical needs where we can deliver meaningful clinical outcomes.
Faster Time to Market
Drug repurposing dramatically accelerates the path from concept to patient, leveraging existing safety and efficacy data.
Lowered Risk
By building on molecules with known safety profiles, we significantly reduce clinical risk compared to de novo drug development.
Exceptional ROI
DRPx development costs a fraction of traditional drug development, creating compelling value for investors and patients alike.
The DRPx Advantage
Drug Repurposing (DRPx) delivers transformative improvements across every dimension of pharmaceutical development.
$50M vs $1Bn traditional development
vs 14 years for traditional drug development
vs 1 in 100,000 for traditional approaches
Collaboration
OrchestratePharma works with a network of academic institutions, CROs, and industry partners to advance its pipeline. Our collaborative approach ensures we leverage the best expertise at every stage of development.
Repurposing for Speed & Efficiency
By repurposing existing approved drugs, we can bypass years of preclinical development and early-phase safety studies. This approach reduces development timelines from 14 years to as little as 5 years, while reducing costs to approximately 1/20th of traditional development.
Holistic Solutions
Our approach goes beyond single-indication drug development. We see fexofenadine as a platform molecule capable of addressing multiple dermatological and inflammatory conditions, creating a diversified portfolio that maximizes value for patients and investors.